Medical devices, healthcare technology and the business of care
PMA approval · P180002

Zephyr Endobronchial Valve System

Pulmonx Corporation · Decision date Jun 29, 2018

FDA DECISIONP180002

What did the FDA approve?

FDA records P180002 as an original PMA application. The recorded decision is approval, dated Jun 29, 2018.

FDA approval order statement

Approval of the Pulmonx Zephyr Endobronchial Valve System. The device is an implantable bronchial valve indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation.
Regulatory pathway
Original PMA
Clinical specialty
Anesthesiology
Decision date
Jun 29, 2018

FDA source record

Regulatory record facts

Identifier
P180002
Regulatory pathway
Premarket approval application
Product code
NJK
Decision code
APPR
Decision date
Jun 29, 2018
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Valve, pulmonary.

Product code
NJK
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P180002 received

    Application receipt date recorded by FDA.

  2. P180002 · FDA decision

    APPR

  3. P180002/S032 · Related supplement

    Zephyr Endobronchial Valve System

Timeline entries are records held by MedtechLedger for P180002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180002

Product / regulatory recordCompanyPathwayDecision dateSource
Pulmonx CorporationPMA supplementSep 11, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Pulmonx Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
700 Chesapeake Dr., Redwood City, CA, 94063

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records